Association of tumor mutational burden with efficacy of Pembrolizumab±Chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study

by on 10 d'octubre de 2022 with No hi ha comentaris
  • Lee, K. -., Van Cutsem, E., Bang, Y. -., Fuchs, C. S., Kudaba, I., Garrido, M., Tabernero, J., . . . Wyrwicz, L. (2022). Association of tumor mutational burden with efficacy of Pembrolizumab±Chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clinical Cancer Research, 28(16), 3489-3498. https://doi.org/10.1158/1078-0432.CCR-22-0121

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *